Liver disease in the patient with fontan circulation

Congenital Heart Disease

Volumn 6, Issue 3, 2011, Pages 190-201

  Wu, Fred M ^a,b   Ukomadu, Chinweike ^c   Odze, Robert D ^d   Valente, Anne Marie ^a,b   Mayer Jr , John E ^a   Earing, Michael G ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Division of Cardiology   (United States)

^c Division of Gastroenterology   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adult Congenital Heart Disease; Fontan Circulation; Liver Disease

Indexed keywords

ALKALINE PHOSPHATASE; AMIODARONE; AMMONIA; AUTACOID; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

AMMONIA BLOOD LEVEL; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; FONTAN PROCEDURE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; HYPOXEMIA; LIVER BLOOD FLOW; LIVER CONGESTION; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LIVER VEIN THROMBOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; SYMPTOM;

FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; LIVER CIRCULATION; LIVER DISEASES; PROGNOSIS; PULMONARY CIRCULATION; RISK ASSESSMENT; RISK FACTORS;

EID: 79956263980     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2011.00504.x     Document Type: Article

References (76)

1. Fontan F, Mounicot FB, Baudet E, Simonneau J, Gordo J, Gouffrant JM. ["Correction" of tricuspid atresia. 2 cases "corrected" using a new surgical technic]. Ann Chir Thorac Cardiovasc. 1971;10:39-47.
2. Khairy P, Fernandes SM, Mayer JE Jr., etal. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85-92.
3. Lemmer JH, Coran AG, Behrendt DM, Heidelberger KP, Stern AM. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg. 1983;86:757-760.
4. Cromme-Dijkhuis AH, Hess J, Hahlen K, etal. Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg. 1993;106:1126-1132.
5. Kaulitz R, Luhmer I, Bergmann F, Rodeck B, Hausdorf G. Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function. Heart. 1997;78:154-159.
6. van Nieuwenhuizen RC, Peters M, Lubbers LJ, Trip MD, Tijssen JG, Mulder BJ. Abnormalities in liver function and coagulation profile following the Fontan procedure. Heart. 1999;82:40-46.
7. Tomita H, Yamada O, Ohuchi H, etal. Coagulation profile, hepatic function, and hemodynamics following Fontan-type operations. Cardiol Young. 2001;11:62-66.
8. Narkewicz MR, Sondheimer HM, Ziegler JW, etal. Hepatic dysfunction following the Fontan procedure. J Pediatr Gastroenterol Nutr. 2003;36:352-357.
9. Driscoll DJ. Long-term results of the Fontan operation. Pediatr Cardiol. 2007;28:438-442.
10. Condurache CT, Johnsrude CL, Bryant K, Recto MR. Ascites secondary to indolent pacemaker infection in a Fontan patient. Tex Heart Inst J. 2008;35:342-344.
11. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg. 2006;82:695-700.
12. Kiesewetter CH, Sheron N, Vettukattill JJ, etal. Hepatic changes in the failing Fontan circulation. Heart. 2007;93:579-584.
13. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611-1624.
14. Ozaki K, Kodama M, Yamashita F, etal. Esophageal varices without portosystemic venous pressure gradient in a patient with post-pericardiotomy constrictive pericarditis: a case report. J Cardiol. 2005;45:161-164.
15. Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology. 1996;23:1047-1052.
16. Munoz SJ. Hepatic encephalopathy. Med Clin North Am. 2008;92:795-812, viii.
17. Chaloupecky V, Svobodova I, Hadacova I, etal. Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up. Heart. 2005;91:73-79.
18. Camposilvan S, Milanesi O, Stellin G, Pettenazzo A, Zancan L, D'Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg. 2008;86:177-182.
19. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J. 1951;13:273-293.
20. Cheung EW, Chay GW, Ma ES, Cheung YF. Systemic oxygen saturation and coagulation factor abnormalities before and after the Fontan procedure. Am J Cardiol. 2005;96:1571-1575.
21. Odegard KC, McGowan FX Jr., DiNardo JA, etal. Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. J Thorac Cardiovasc Surg. 2002;123:459-465.
22. Odegard KC, McGowan FX Jr., Zurakowski D, etal. Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg. 2002;73:1770-1777.
23. Richman SM, Delman AJ, Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med. 1961;30:211-225.
24. Hsia TY, Khambadkone S, Deanfield JE, Taylor JF, Migliavacca F, De Leval MR. Subdiaphragmatic venous hemodynamics in the Fontan circulation. J Thorac Cardiovasc Surg. 2001;121:436-447.
25. Hsia TY, Khambadkone S, Redington AN, De Leval MR. Instantaneous pressure-flow velocity relations of systemic venous return in patients with univentricular circulation. Heart. 2000;83:583.
26. Hsia TY, Khambadkone S, Redington AN, de Leval MR. Effect of fenestration on the sub-diaphragmatic venous hemodynamics in the total-cavopulmonary connection. Eur J Cardiothorac Surg. 2001;19:785-792.
27. Hsia TY, Khambadkone S, Redington AN, Migliavacca F, Deanfield JE, de Leval MR. Effects of respiration and gravity on infradiaphragmatic venous flow in normal and Fontan patients. Circulation. 2000;102:III148-III153.
28. Moreno AH, Burchell AR. Respiratory regulation of splanchnic and systemic venous return in normal subjects and in patients with hepatic cirrhosis. Surg Gynecol Obstet. 1982;154:257-267.
29. Bryant T, Ahmad Z, Millward-Sadler H, etal. Arterialised hepatic nodules in the Fontan circulation: hepatico-cardiac interactions. Int J Cardiol. 2010; doi:10.1016/j.ijcard.2010.05.047. Available online 16 June 2010.
30. Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348-1352.
31. Kendall TJ, Stedman B, Hacking N, etal. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol. 2008;61:504-508.
32. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21:1232-1237.
33. Ghosh ML, Emery JL. Hypoxia and asymmetrical fibrosis of the liver in children. Gut. 1973;14:209-212.
34. Henriksson P, Varendh G, Lundstrom NR. Haemostatic defects in cyanotic congenital heart disease. Br Heart J. 1979;41:23-27.
35. Wedemeyer AL, Edson JR, Krivit W. Coagulation in cyanotic congenital heart disease. Am J Dis Child. 1972;124:656-660.
36. Jenkins JG, Lynn AM, Wood AE, Trusler GA, Barker GA. Acute hepatic failure following cardiac operation in children. J Thorac Cardiovasc Surg. 1982;84:865-871.
37. Matsuda H, Covino E, Hirose H, etal. Acute liver dysfunction after modified Fontan operation for complex cardiac lesions. Analysis of the contributing factors and its relation to the early prognosis. J Thorac Cardiovasc Surg. 1988;96:219-226.
38. Higashiyama H, Yamaguchi M, Kumada K, Sasaki H, Yamaguchi T, Ozawa K. Functional deterioration of the liver by elevated inferior vena cava pressure: a proposed upper safety limit of pressure for maintaining liver viability in dogs. Intensive Care Med. 1994;20:124-129.
39. Goto T, Mikami KI, Miura K, etal. Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells. Pathophysiology. 2004;11:153-158.
40. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992;15:350-353.
41. Alter MJ, Kruszon-Moran D, Nainan OV, etal. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
42. Wang A, Book WM, McConnell M, Lyle T, Rodby K, Mahle WT. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to screening in 1992. Am J Cardiol. 2007;100:1307-1309.
43. Vogt M, Lang T, Frosner G, etal. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866-870.
44. Vogt M, Muhlbauer F, Braun SL, etal. Prevalence and risk factors of hepatitis C infection after cardiac surgery in childhood before and after blood donor screening. Infection. 2004;32:134-137.
45. Pollak PT. How toxic is amiodarone to the liver? J Gastrointestin Liver Dis. 2010;19:11-13.
46. Mattar W, Juliar B, Gradus-Pizlo I, Kwo PY. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis. 2009;18:419-423.
47. Allen LA, Felker GM, Pocock S, etal. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11:170-177.
48. Ewe SH, Tan JL. Hepatotocellular carcinoma-a rare complication post Fontan operation. Congenit Heart Dis. 2009;4:103-106.
49. Babaoglu K, Binnetoglu FK, Aydogan A, etal. Hepatic adenomatosis in a 7-year-old child treated earlier with a Fontan procedure. Pediatr Cardiol. 2010;31:861-864.
50. Saliba T, Dorkhom S, O'Reilly EM, Ludwig E, Gansukh B, Abou-Alfa GK. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:889-891.
51. Barberis VI, Brili S, Dimopoulou M, Barbetseas J, Stefanadis C. Hepatocellular carcinoma with right atrial extension in a young patient with congenitally unguarded tricuspid orifice. Echocardiography. 2006;23:417-420.
52. Ho SS, Brown R, Fitzgibbon B. Hepatocellular carcinoma with cardiac cirrhosis. Med J Aust. 1990;152:553-554.
53. Izumi Y, Hiramatsu N, Itose I, etal. Juvenile hepatocellular carcinoma with congestive liver cirrhosis. J Gastroenterol. 2005;40:204-208.
54. Song PS, Koh KC, Yoo BC, etal. [A case of hepatocellular carcinoma complicating cardiac cirrhosis caused by constrictive pericarditis]. Korean J Gastroenterol. 2005;45:436-440.
55. Friedman SL. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Nat Clin Pract Gastroenterol Hepatol. 2007;4:236-237.
56. Kweon YO, Goodman ZD, Dienstag JL, etal. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35:749-755.
57. Poynard T, McHutchison J, Manns M, etal. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.
58. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127:981-985.
59. Hammel P, Couvelard A, O'Toole D, etal. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001;344:418-423.
60. Crespo-Leiro MG, Robles O, Paniagua MJ, etal. Reversal of cardiac cirrhosis following orthotopic heart transplantation. Am J Transplant. 2008;8:1336-1339.
61. Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, etal. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004;44:2065-2072.
62. Lamour JM, Kanter KR, Naftel DC, etal. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54:160-165.
63. Bernstein D, Naftel D, Chin C, etal. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation. 2006;114:273-280.
64. Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981;3 (suppl 1):73-80.
65. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007;113:109-118.
66. Brilla CG, Maisch B. Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. Eur Heart J. 1994;15 (suppl D):45-52.
67. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 1990;67:787-794.
68. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-1867.
69. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res. 1996;33:315-326.
70. Caligiuri A, De Franco RM, Romanelli RG, etal. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology. 2003;124:504-520.
71. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg. 2006;82:e39-e40.
72. Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2006;132:1232-1233.
73. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681-1687.
74. Hager A, Fratz S, Hess J. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2009;30:507-508; author reply 8.
75. Reinhardt Z, Uzun O, Bhole V, etal. Sildenafil in the management of the failing Fontan circulation. Cardiol Young. 2010;20:522-525.
76. Uhm JY, Jhang WK, Park JJ, Seo DM, Yun SC, Yun TJ. Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. Pediatr Cardiol. 2010;31:515-520.